Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CELC 
Celcuity LLC (CELC)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/22/2025: CELC (5-star) is a STRONG-BUY. BUY since 2 days. Simulated Profits (6.93%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $81.12
1 Year Target Price $81.12
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 230.26% | Avg. Invested days 41 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/22/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.78B USD | Price to earnings Ratio - | 1Y Target Price 81.12 |
Price to earnings Ratio - | 1Y Target Price 81.12 | ||
Volume (30-day avg) 7 | Beta 0.71 | 52 Weeks Range 7.58 - 83.00 | Updated Date 10/22/2025 |
52 Weeks Range 7.58 - 83.00 | Updated Date 10/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.47 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -38.49% | Return on Equity (TTM) -134.54% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2027757057 | Price to Sales(TTM) - |
Enterprise Value 2027757057 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -7.8 | Shares Outstanding 42426711 | Shares Floating 18694906 |
Shares Outstanding 42426711 | Shares Floating 18694906 | ||
Percent Insiders 12.05 | Percent Institutions 84.53 |
Upturn AI SWOT
Celcuity LLC
Company Overview
History and Background
Celcuity LLC is a company focused on improving outcomes for cancer patients through innovative diagnostic tests. Founded in 2011, it has concentrated on developing and commercializing diagnostic platforms that help identify cancer subtypes to improve therapy selection.
Core Business Areas
- Cellular Analysis: This segment focuses on the development and commercialization of diagnostic tests that analyze live tumor cells to predict a patient's response to cancer therapy.
Leadership and Structure
Celcuity LLC is led by its executive team, and it operates with a focus on precision medicine for cancer treatment. Key personnel drive the company's research, development, and commercialization efforts.
Top Products and Market Share
Key Offerings
- CELsignia Multi-Pathway Activity Test: This diagnostic test is designed to identify the signaling pathways driving cancer growth, enabling physicians to select more effective targeted therapies. Market share information is not publicly available due to the specialized nature of the diagnostic market and is difficult to ascertain. Competitors include companies offering similar diagnostic services and broader genomic profiling tests.
Market Dynamics
Industry Overview
The market for cancer diagnostics is growing rapidly, driven by advances in genomics and personalized medicine. There is increasing demand for tests that can predict treatment response and guide therapy selection.
Positioning
Celcuity LLC is positioned within the precision medicine space, focusing on functional diagnostics. Its advantage lies in its ability to analyze live cells and signaling pathways, offering insights beyond genomic profiling.
Total Addressable Market (TAM)
The TAM for cancer diagnostics is estimated to be in the tens of billions of dollars annually. Celcuity LLC is targeting specific segments within this market, related to personalized therapy selection.
Upturn SWOT Analysis
Strengths
- Proprietary diagnostic platform
- Focus on personalized medicine
- Potential to improve cancer treatment outcomes
Weaknesses
- Limited commercial traction
- Reliance on single product
- High research and development costs
Opportunities
- Expanding applications of diagnostic platform
- Partnerships with pharmaceutical companies
- Increasing adoption of personalized medicine
Threats
- Competition from larger diagnostic companies
- Regulatory hurdles
- Reimbursement challenges
Competitors and Market Share
Key Competitors
Competitive Landscape
N/A
Growth Trajectory and Initiatives
Historical Growth: N/A
Future Projections: N/A
Recent Initiatives: N/A
Summary
Celcuity LLC is a private company focused on advancing cancer diagnostics. Its CELsignia platform offers potential in personalized medicine, but it faces challenges related to commercial traction and competition. The growth hinges on successful partnerships and expansion of its platform's applications.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Celcuity LLC's website
- Industry reports on cancer diagnostics
Disclaimers:
The information provided is based on publicly available data and general industry knowledge. Due to Celcuity LLC being a private company, financial data and market share information are limited. This analysis is for informational purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Celcuity LLC
Exchange NASDAQ | Headquaters Minneapolis, MN, United States | ||
IPO Launch date 2017-09-20 | Co-Founder, Chairman & CEO Mr. Brian F. Sullivan | ||
Sector Healthcare | Industry Biotechnology | Full time employees 87 | Website https://www.celcuity.com |
Full time employees 87 | Website https://www.celcuity.com | ||
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). It also engages in developing of CELsignia diagnostic platform. The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.